Curated News
By: NewsRamp Editorial Staff
June 06, 2024
Clene (NASDAQ: CLNN) to Present at Emerging Growth Conference on June 12, 2024
Discuss on Reddit
GithubTLDR
- Clene (NASDAQ: CLNN) to present at Emerging Growth Conference, providing insights into breakthrough therapies for neurodegenerative diseases.
- Interested parties can register to view the corporate presentation at https://ibn.fm/A217J and access the replay on the Events section of the Clene website.
- Clene is focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, offering hope for patients with ALS, Parkinson’s, and multiple sclerosis.
- CNM-Au8(R) is an investigational first-in-class therapy that targets mitochondrial function and the NAD pathway while reducing oxidative stress, representing a potential breakthrough in neurodegenerative disease treatment.
Impact - Why it Matters
This news matters as it provides insight into Clene's efforts to develop a first-in-class therapy for neurodegenerative diseases, potentially impacting the lives of those suffering from conditions like ALS, Parkinson's, and MS.
Summary
Clene (NASDAQ: CLNN) and its subsidiary Clene Nanomedicine Inc. will present at the Emerging Growth Conference on June 12, 2024, discussing their focus on improving mitochondrial health to treat neurodegenerative diseases. The webcast will be available for interested parties to view and a replay will be accessible as well. CNM-Au8(R) is their investigational therapy for ALS, Parkinson's, and MS, targeting mitochondrial function and reducing oxidative stress.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Clene (NASDAQ: CLNN) to Present at Emerging Growth Conference on June 12, 2024
